Clinical trial
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
NCT00053326 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00053326 |
|---|---|
| Title | Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma |
| Official title | A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children With Recurrent/Resistant High Risk Neuroblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Neuroblastoma |
| Intervention type | Drug, Other |
| Interventions | fenretinide, pharmacological study |
| Enrollment | 70 |
| Start date | May 1, 2003 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 28, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: